Incyte (INCY) Tops Q2 EPS by 5c
Incyte (NASDAQ: INCY) reported Q2 EPS of $0.80, $0.05 better than the analyst estimate of $0.75. Revenue for the quarter came in at $705.7 million versus the consensus estimate of $686.98 million.
Guidance:
|
| |
| Current | Previous |
Jakafi net product revenues | $2,125 - $2,170 million | $2,125 - $2,200 million |
Other Hematology/Oncology net product revenues | $155 - $170 million | $145 - $160 million |
GAAP Cost of product revenues | 6 – 7% of net product revenues | Unchanged |
Non-GAAP Cost of product revenues1 | 5 – 6% of net product revenues | Unchanged |
GAAP Research and development expenses | $1,350 - $1,390 million | Unchanged |
Non-GAAP Research and development expenses2 | $1,220 - $1,250 million | Unchanged |
GAAP Selling, general and administrative expenses | $725 - $755 million | $735 - $775 million |
Non-GAAP Selling, general and administrative expenses3 | $655 - $680 million | $665 - $700 million |
For earnings history and earnings-related data on Incyte (INCY) click here.